Hyperspectral imaging company Optina Diagnostics revealed on Wednesday the receipt of the US Food and Drug Administration's (FDA) breakthrough device designation for its retinal imaging platform (CAPRS1/MHRC2) that uses Artificial Intelligence (AI) to analyse the data rich hyperspectral retinal images captured during a simple eye scan in the diagnosis of Alzheimer's Disease, the most common type of dementia.
The CAPRS1/MHRC2 platform is intended for the detection of likely positron-emission tomography (PET) amyloid status (negative or positive) as well as to aid in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
Amyloid PET is the standard method for the detection of amyloid plaques in the brain, a key hallmark of Alzheimer's disease.
Following the US FDA's breakthrough device designation, the company is working towards a non-invasive and more accessible means via a simple eye imaging test to improve the diagnosis accuracy and management of patients evaluated for Alzheimer's disease or other form of cognitive decline.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project